Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 606-615

  Verhamme, Katia M C ^a   Afonso, Ana ^a   Romio, Silvana ^a   Stricker, Bruno C ^a   Brusselle, Guy G O ^a,b   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TIOTROPIUM BROMIDE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEVICE SAFETY; FEMALE; FOLLOW UP; HUMAN; INHALER; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COHORT; MORTALITY; TIOTROPIUM HANDIHALER; TIOTROPIUM RESPIMAT SOFT MIST INHALER;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84883495199     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00005813     Document Type: Article

References (30)

1. World Health Organization (WHO). The world health report 2008 - primary health care (now more than ever). 2008. www.who.int/whr/2008/08-chap1-en.pdf Date last accessed: June 27, 2013.
2. Global Strategy for Diagnosis, Management, and Prevention of COPD. 2011.
3. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-862. (Pubitemid 44570305)
4. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-1449. (Pubitemid 36549761)
5. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
6. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
7. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224. (Pubitemid 34162820)
8. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during one year's treatment with toptropium. Eur Resp J 2002; 19: 209-216. (Pubitemid 34162819)
9. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55. (Pubitemid 34754142)
10. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404. (Pubitemid 36560942)
11. Okudan N, Gok M, Gokbel H, et al. Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease. Lung 2006; 184: 201-204. (Pubitemid 44477405)
12. van Noord JA, Cornelissen PJ, Aumann JL, et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009; 103: 22-29.
13. Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18: 264-272. (Pubitemid 41395728)
14. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chronic Obstruct Pulmon Dis 2007; 2: 559-565.
15. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
16. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama 2008; 300: 1439-1450.
17. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med 2010; 363: 1097-1099.
18. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215.
19. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease; systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68: 48-56.
20. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993; 119: 1036-1041. (Pubitemid 23334661)
21. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992; 9: 330-339.
22. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 339-344. (Pubitemid 30030067)
23. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-595. (Pubitemid 41179489)
24. Curkendall SM, Lanes S, de Luise C, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006; 21: 803-813. (Pubitemid 44885203)
25. Eisner MD, Trupin L, Katz PP, et al. Development and validation of a survey-based COPD severity score. Chest 2005; 127: 1890-1897.
26. Soriano JB, Maier WC, Visick G, et al. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17: 1075-1080.
27. de Vries F, Setakis E, Zhang B, et al. Long-acting β2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010; 36: 494-502.
28. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344: e977.
29. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med, 104: 228-236.
30. ClinicalTrials.gov. NCT 01126437 Comparison of tiotropium in the Handihaler versus the Respimat in COPD. 2012.